Sign in

    Sa'ar Yaniv

    Stock Analyst and Biotech Analyst at Roth Capital

    Sa'ar Yaniv is a Stock Analyst and Biotech Analyst at Roth Capital, specializing in healthcare with a particular focus on biotechnology companies. He has covered companies such as Galectin Therapeutics and Concert Pharmaceuticals, achieving a 33.33% success rate and an average return of 4.06% on his stock recommendations. Since joining Roth, Yaniv has produced research primarily in the biotech sector and participated in industry events, bringing experience in clinical trial analysis and industry trends to his coverage. His professional credentials include formal recognition as a research analyst with assignments involving detailed data compilation and direct interaction with company management.

    Sa'ar Yaniv's questions to GALECTIN THERAPEUTICS (GALT) leadership

    Sa'ar Yaniv's questions to GALECTIN THERAPEUTICS (GALT) leadership • Q4 2016

    Question

    Sa'ar Yaniv from Roth Capital asked for specifics on the NASH cirrhosis study timeline, including last patient completion and data compilation. He also inquired about interim analyses, the rationale for the high expected dropout rate, pre-specified subgroup analyses, the status of the non-cirrhotic NASH program, future plans for the dermatology programs, and publication plans for recent data.

    Answer

    President and CEO Peter Traber confirmed the last patient's final visit would lead to a database lock around mid-October, with top-line data reported in December. He noted that while there are three scheduled safety reviews by a DSMB, there is no interim efficacy analysis. The high 25% dropout rate was a conservative estimate recommended by the FDA based on historical trials. Dr. Traber also stated the non-cirrhotic NASH program is not being pursued, the atopic dermatitis program may be advanced pending funding, and that manuscripts for the NASH-FX and psoriasis data are in preparation.

    Ask Fintool Equity Research AI